ADMA Q2 2020 Earnings — ADMA Biologics, Inc. Revenue & Financial Results | Market Cap Arena

ADMAADMA Biologics, Inc.

$4B

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M+18.7% YoY

Gross Profit

-$6M-73.3% margin

Operating Income

-$17M-219.9% margin

Net Income

-$20M-259.1% margin

EPS (Diluted)

$-0.23

QoQ Revenue Growth

-23.6%

Cash Flow

Operating Cash Flow

-$21M

Free Cash Flow

-$25M

Stock-Based Comp.

$715,608

Balance Sheet

Total Assets

$192M

Total Liabilities

$115M

Stockholders' Equity

$77M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$7M	+18.7%
Gross Profit	-$6M	-$4M	-45.2%
Operating Income	-$17M	-$11M	-51.0%
Net Income	-$20M	-$13M	-52.7%